

Press Release

Zug, 21 March 2013

Successful IPO for Enanta Pharmaceuticals

Enanta Pharmaceuticals (NASDAQ: ENTA), a portfolio company of HBM Healthcare Investments, has successfully completed its planned initial public offering (IPO). The issue of 4 million shares at a price of USD 14 per share raised a total of USD 56 million for the company. The shares of Enanta have been traded on the US Nasdaq exchange under the symbol "ENTA" since 21 March 2013 and closed at a price of USD 17.18 (+22.7%) on the first trading day.

HBM Healthcare Investments had invested USD 7.7 million in Enanta at an average price of USD 8.47 per share before the company went public and also participated in the IPO. Based on the closing share price on the first trading day, the net asset value per share (NAV) of HBM Healthcare Investments has risen by CHF 1.05 (+1.6%).

Enanta is currently developing a series of drugs for the treatment of Hepatitis C. In 2006, the company entered into a strategic partnership with AbbVie Inc. (NYSE: ABBV) for the most advanced phase III programme among these drug candidates. In early 2012, Enanta signed a separate collaboration agreement with Novartis (SIX: NOVN; NYSE: NVS) for a further programme, which is currently in phase I clinical development. These two partnerships entitle Enanta to milestone payments of several hundred million US Dollars, as well as double-digit royalties on future sales revenues.

Hepatitis C is an infectious disease caused by the Hepatitis C virus affecting over 170 million people worldwide. The virus is spread through direct contact with the blood of an infected person, and increases a person's risk of chronic liver disease, cirrhosis, liver cancer and death.

For further information, please contact Dr. Andreas Wicki, tel.: +41 41 768 11 08, andreas.wicki@hbmhealthcare.com

NOT FOR DISTRIBUTION IN USA, CANADA, JAPAN OR AUSTRALIA

HBM Healthcare Investments

Enanta Pharmaceuticals

Enanta Pharmaceuticals is a research and development company focused on developing best-in-class small-molecule drugs in the infectious disease field. Enanta is developing novel protease, NS5A, nucleoside(tide) polymerase, and cyclophilin-based inhibitors targeted at the Hepatitis C virus (HCV). Additionally, the company has created a new class of antibiotics, called bicycloides, which overcome bacterial resistance. Enanta is a privately held company headquartered in Watertown, Massachusetts. Further information on Enanta is available on the company's website at www.enanta.com.

Profile of HBM Healthcare Investments Ltd

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of some twenty five promising companies in the biotechnology/human medicine, medical technology and diagnostics sectors. Many of these companies have their lead products already available on the market, or at an advanced stage of development. The focus of investment is on follow-on financing for existing portfolio companies. These portfolio companies are closely tracked and actively guided on their strategic directions. This is what makes HBM Healthcare Investments an interesting alternative to investing in big pharma and biotech companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (Wertpapierprospektgesetz). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM Healthcare Investments have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

HBM Healthcare Investments Ltd